drugset / Trial / NCT01460888
Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
Phase 1
Unknown
36 enrolled
The Christie NHS Foundation Trust
AstraZeneca · collabCancer Research UK · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer who are unsuitable for platinum containing chemotherapy.
Timeline
- Start
- 2013-07
- Primary completion
- 2015-07
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 25 mg | Oral |
| Subject | Olaparib | Small molecule | 50 mg | Oral |
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |